MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

0.98 1.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.96

Max

0.99

Põhinäitajad
By Trading Economics
Sissetulek	1.8M -32M
Müük	-166K 1.7M
Kasumimarginaal	-1,852.384
Töötajad	181
EBITDA	7.9M -29M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+405.05% upside

Turustatistika
By TradingEconomics
Turukapital	-11M 115M
Eelmine avamishind	-0.05
Eelmine sulgemishind	0.98

Uudiste sentiment

By Acuity

50%

146 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. jaan 2026, 22:45 UTC

Suurimad hinnamuutused turgudel

GH Research Shares Up, Plans to Provide Update on New Drug Application

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Geopolitical Risks After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:50 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Decline After Removal of Venezuela's Maduro -- Market Talk

4. jaan 2026, 23:41 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

4. jaan 2026, 23:40 UTC

Market Talk

Uudisväärsed sündmused

Markets Mostly Calm as Venezuelan Raid Weighed -- Market Talk

4. jaan 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Declines on Oversupply Worries After Maduro's Ouster -- Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 23:19 UTC

Market Talk

Uudisväärsed sündmused

ONGC Could Receive $500M in Unpaid Dividends From U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 23:17 UTC

Uudisväärsed sündmused

Spot Gold Rises 0.8% to $4,365.24/oz

4. jaan 2026, 23:16 UTC

Uudisväärsed sündmused

Spot Gold Rises After U.S.' Removal of Venezuela's Maduro

4. jaan 2026, 23:14 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Fall 0.6%; Front-Month Brent Crude Oil Futures Drop 0.5%

4. jaan 2026, 23:13 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Fall After Ouster of Venezuela's Maduro

4. jaan 2026, 23:12 UTC

Market Talk

Uudisväärsed sündmused

Reliance Industries' Could Benefit from U.S. Takeover of Venezuelan Oil -- Market Talk

4. jaan 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Gold Can Gain From Flight to Quality, Central Bank Demand After Maduro Ouster -- Market Talk

4. jaan 2026, 21:00 UTC

Tulu

An On-Time Jobs Report. Plus, Albertsons, Constellation, Jefferies, and More Stocks to Watch this Week. -- Barrons.com

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

4. jaan 2026, 20:49 UTC

Market Talk

Uudisväärsed sündmused

Jitters About Potential for U.S. Actions Elsewhere Could Grow -- Market Talk

3. jaan 2026, 18:59 UTC

Uudisväärsed sündmused

Update: Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 17:42 UTC

Uudisväärsed sündmused

The Oil Sector's Biggest Winners and Losers From Venezuela Regime Change -- Barrons.com

3. jaan 2026, 17:40 UTC

Uudisväärsed sündmused

Trump Says U.S. Will 'Run' Venezuela After Maduro Is Flown to New York -- Barrons.com

3. jaan 2026, 16:10 UTC

Uudisväärsed sündmused

What Maduro's Capture Means for Chevron Stock -- Barrons.com

3. jaan 2026, 15:53 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 15:03 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 14:10 UTC

Uudisväärsed sündmused

Update: Venezuela's Maduro Captured by U.S. and Flown Out of Country, Trump Says -- Barrons.com

3. jaan 2026, 12:16 UTC

Uudisväärsed sündmused

U.S. Captures Maduro, Trump Says -- Barrons.com

3. jaan 2026, 09:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

3. jaan 2026, 09:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

3. jaan 2026, 00:43 UTC

Omandamised, ülevõtmised, äriostud

Research Reports -- Barrons.com

2. jaan 2026, 22:13 UTC

Market Talk

Tulu

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. jaan 2026, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

405.05% tõus

12 kuu keskmine prognoos

Keskmine 5 USD 405.05%

Kõrge 8 USD

Madal 2 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

146 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.